Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2023 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are doing and scaling. Let me analyze the transcript carefully. The key counterparties mentioned are: 1. AbbVie (Allergan) - for dermal filler collaboration 2. Stratasys - for bioprinting collaboration Let me check each condition: (1) Does management speak about counterparties' business as part of its own? - Yehiel Tal says: "In their full year and fourth quarter conference call, AbbVie stated that they expect meaningful growth in the aesthetics market and that importantly, a ramping up is now anticipated after multiple quarters of decline in the U.S. filler market." - This is reporting on AbbVie's own market expectations and ramp. However, this is about the market, not specifically about AbbVie's own scaling of the product. - The dermal filler is "now in the clinical phase of development" - so it's not yet commercialized. (2) Is the company already inside that growth? - For AbbVie: The collaboration exists, and a $10 million milestone was achieved. But the product is still in clinical phase - not yet commercial. The company is receiving milestone payments, not product revenue from sales. - For Stratasys: They have a joint development agreement for bioprinting breast implants - this is development, not commercial supply. (3) Is the counterparties' trajectory early and large relative to the company? - The dermal filler is in clinical phase - so the commercial ramp hasn't started. AbbVie's statements about market growth are about the aesthetics market generally, not about their specific product ramp. - The breast implant program is in animal studies. The question asks whether management's forward account consists of reporting on the growth/expansion/ramp of specific customers/partners that the company ALREADY SUPPLIES OR SERVES, such that the company's own coming volume is presented as a consequence of those parties' trajectories. Looking at the transcript: - The AbbVie collaboration is in clinical phase - the product hasn't launched. Management mentions AbbVie's expectations about the aesthetics market, but this is about the market, not about AbbVie's own scaling of the specific product. - The company's forward outlook is mostly about its own development programs: breast implants, gut-on-a-chip (put on hold), etc.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.